Biosimilar Market and Cost Analysis

The biosimilar market is growing at an threatening rate. The CAGR (Compound annual growth rate) from 2016 to 2020 is projected at over 22%. The biosimilars market is going to be around $6.2 billion by 2020. At the end of this decennary the biosimilars would surely occupy 27% of the total pharmaceutical market. The estimated cost savings potential of biological products are around $54 billion over ten years .The upcoming biologics are more costly it’s about $100,000 per. However, with all the success stories there also some failure rate in manufacturing and obtaining license towards marketing of biosimilars

  • Pharmacoeconomic Modelling of Biosimilars
  • Risk management plan (RMP) for Biosimilars
  • Return on Investment (ROI) for Biosimilars
  • CAGR of biologics and biosimilars
  • Penetration and uptake of biosimilars in different disease sectors

Related Conference of Biosimilar Market and Cost Analysis

August 20-21, 2018

12th Asian Biologics and Biosimilars Congress

Tokyo, Japan
August 29-30, 2018 |

International Conference and Exhibition on Drug Safety & Pharmacovigilance

Park Inn By Radisson, Toronto, Canada
October 18-20, 2018

18th World Pharma Congress

Warsaw, Poland
November 14-15, 2018

13th International Conference on Biosimilars and Biologics

Lisbon, Portugal
November 15-16, 2018

14th International Conference on Generic Drugs and Biosimilars

Frankfurt, Germany
September 18-19, 2018

6 th European Biopharma Congress

Amsterdam, Netherlands

Biosimilar Market and Cost Analysis Conference Speakers

Recommended Sessions

Related Journals

Are you interested in